Esther H. Lips

6.0k total citations
84 papers, 2.7k citations indexed

About

Esther H. Lips is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Esther H. Lips has authored 84 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 48 papers in Cancer Research and 28 papers in Molecular Biology. Recurrent topics in Esther H. Lips's work include Breast Cancer Treatment Studies (33 papers), Cancer Genomics and Diagnostics (18 papers) and BRCA gene mutations in cancer (15 papers). Esther H. Lips is often cited by papers focused on Breast Cancer Treatment Studies (33 papers), Cancer Genomics and Diagnostics (18 papers) and BRCA gene mutations in cancer (15 papers). Esther H. Lips collaborates with scholars based in Netherlands, United States and United Kingdom. Esther H. Lips's co-authors include Jelle Wesseling, Sjoerd Rodenhuis, Petra M. Nederlof, Lennart Mulder, Lodewyk F.A. Wessels, Tom van Wezel, Emiel J. Rutgers, Jorma J. de Ronde, Marte C. Liefaard and Hans Morreau and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Esther H. Lips

81 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Esther H. Lips Netherlands	30	1.2k	1.2k	1.1k	530	481	84	2.7k
Steven McKinney Canada	18	977 0.8×	1.2k 1.0×	1.2k 1.1×	374 0.7×	346 0.7×	30	2.9k
Abeer M. Shaaban United Kingdom	33	1.2k 1.0×	1.1k 0.9×	1.0k 0.9×	700 1.3×	873 1.8×	164	3.2k
Coya Tapia Switzerland	28	752 0.6×	1.1k 0.9×	838 0.7×	283 0.5×	253 0.5×	47	2.3k
Magali Lacroix‐Triki France	29	1.4k 1.2×	1.3k 1.1×	1.4k 1.2×	314 0.6×	648 1.3×	89	3.1k
Maryse Fiche France	29	976 0.8×	1.6k 1.4×	1.2k 1.1×	553 1.0×	543 1.1×	83	3.4k
Pascal Bonnier France	31	1.1k 0.9×	1.4k 1.2×	895 0.8×	331 0.6×	495 1.0×	90	2.7k
Bo Baldetorp Sweden	32	1.3k 1.1×	1.5k 1.2×	1.4k 1.2×	550 1.0×	807 1.7×	132	3.6k
Susan J. Done Canada	35	1.2k 1.0×	1.3k 1.1×	1.5k 1.3×	383 0.7×	477 1.0×	106	3.2k
Rita A. Sakr United States	24	1.4k 1.1×	1.1k 0.9×	869 0.8×	611 1.2×	692 1.4×	61	2.6k
Thaer Khoury United States	32	1.1k 0.9×	1.5k 1.3×	1.1k 0.9×	266 0.5×	675 1.4×	153	3.1k

Countries citing papers authored by Esther H. Lips

Since Specialization

Citations

This map shows the geographic impact of Esther H. Lips's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther H. Lips with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther H. Lips more than expected).

Fields of papers citing papers by Esther H. Lips

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther H. Lips. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther H. Lips. The network helps show where Esther H. Lips may publish in the future.

Co-authorship network of co-authors of Esther H. Lips

This figure shows the co-authorship network connecting the top 25 collaborators of Esther H. Lips. A scholar is included among the top collaborators of Esther H. Lips based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther H. Lips. Esther H. Lips is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lips, Esther H., Lennart Mulder, Elinor J. Sawyer, et al.. (2025). Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features. EBioMedicine. 116. 105750–105750. 1 indexed citations

Liefaard, Marte C., Anna van der Voort, Maartje van Seijen, et al.. (2024). Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade. npj Breast Cancer. 10(1). 29–29. 10 indexed citations

Liefaard, Marte C., Kat Moore, Lennart Mulder, et al.. (2023). Tumour-educated platelets for breast cancer detection: biological and technical insights. British Journal of Cancer. 128(8). 1572–1581. 14 indexed citations

Hoogstraat, Marlous, Esther H. Lips, Isabel Mayayo‐Peralta, et al.. (2022). Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. npj Breast Cancer. 8(1). 60–60. 23 indexed citations

Steenbruggen, Tessa G., Michael Schaapveld, Hugo M. Horlings, et al.. (2021). Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. JNCI Cancer Spectrum. 5(3). 18 indexed citations

Seijen, Maartje van, Esther H. Lips, Liping Fu, et al.. (2021). Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. British Journal of Cancer. 125(10). 1443–1449. 11 indexed citations

Giardiello, Daniele, Iris Kramer, Maartje J. Hooning, et al.. (2020). Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. npj Breast Cancer. 6(1). 60–60. 10 indexed citations

Engelhardt, Ellen G., Frederieke van Duijnhoven, Maartje van Seijen, et al.. (2020). The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. The Breast. 50. 95–103. 2 indexed citations

Seijen, Maartje van, Esther H. Lips, Alastair M. Thompson, et al.. (2019). Ductal carcinoma in situ: to treat or not to treat, that is the question. British Journal of Cancer. 121(4). 285–292. 191 indexed citations

10.

Visser, Lindy L., Emma J. Groen, Flora E. van Leeuwen, et al.. (2019). Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. Cancer Epidemiology Biomarkers & Prevention. 28(5). 835–845. 44 indexed citations

11.

Liefaard, Marte C., et al.. (2019). Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping. Communications Biology. 2(1). 325–325. 173 indexed citations

12.

Steenbruggen, Tessa G., Maartje van Seijen, Mette S. van Ramshorst, et al.. (2019). Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. Clinical Cancer Research. 25(16). 4985–4992. 16 indexed citations

13.

Meijer, Titia G., Nicole S. Verkaik, Anieta M. Sieuwerts, et al.. (2018). Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clinical Cancer Research. 24(24). 6277–6287. 47 indexed citations

14.

Seijen, Maartje van, Antien L. Mooyaart, Lennart Mulder, et al.. (2017). Enrichment of high-grade tumors in breast cancer gene expression studies. Breast Cancer Research and Treatment. 168(2). 327–335. 4 indexed citations

15.

Lips, Esther H., Lennart Mulder, Gabe S. Sonke, et al.. (2016). BRCA1 -Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency. Clinical Cancer Research. 23(5). 1236–1241. 15 indexed citations

16.

Wijdeven, Ruud H., Baoxu Pang, Sabina Y. van der Zanden, et al.. (2015). Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer. Cancer Research. 75(19). 4176–4187. 56 indexed citations

17.

Oonk, Anne M.M., Lennart Mulder, Nadja Laddach, et al.. (2012). Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Annals of Oncology. 23(9). 2301–2305. 28 indexed citations

18.

Lips, Esther H., Lennart Mulder, Jorma J. de Ronde, et al.. (2011). Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Research and Treatment. 131(3). 827–836. 66 indexed citations

19.

Vollebergh, Marieke A., Esther H. Lips, Petra M. Nederlof, et al.. (2010). An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Annals of Oncology. 22(7). 1561–1570. 126 indexed citations

20.

Lips, Esther H., Ronald van Eijk, Eelco J. R. de Graaf, et al.. (2008). Progression and Tumor Heterogeneity Analysis in Early Rectal Cancer. Clinical Cancer Research. 14(3). 772–781. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact